CINECA IRIS Institutional Research Information System

CONVERTINO, IRMA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.008
AS - Asia 2.898
EU - Europa 2.096
SA - Sud America 512
AF - Africa 263
OC - Oceania 35
Continente sconosciuto - Info sul continente non disponibili 9
Totale 9.821
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.897
SG - Singapore 926
IT - Italia 628
CN - Cina 619
HK - Hong Kong 409
BR - Brasile 383
SE - Svezia 318
VN - Vietnam 301
GB - Regno Unito 226
DE - Germania 207
IN - India 173
FR - Francia 154
BG - Bulgaria 124
FI - Finlandia 113
JP - Giappone 106
CI - Costa d'Avorio 90
TR - Turchia 77
RU - Federazione Russa 66
NL - Olanda 58
SN - Senegal 57
CA - Canada 54
ID - Indonesia 42
AT - Austria 40
BD - Bangladesh 35
PL - Polonia 35
AU - Australia 34
IQ - Iraq 34
NG - Nigeria 34
AR - Argentina 32
MX - Messico 30
KR - Corea 23
CO - Colombia 22
ES - Italia 22
SA - Arabia Saudita 21
CL - Cile 19
EC - Ecuador 19
ZA - Sudafrica 19
UZ - Uzbekistan 18
VE - Venezuela 15
PT - Portogallo 14
EG - Egitto 13
PK - Pakistan 13
UA - Ucraina 13
IR - Iran 12
MA - Marocco 12
MY - Malesia 11
CZ - Repubblica Ceca 10
IE - Irlanda 10
LT - Lituania 10
JO - Giordania 9
KE - Kenya 9
PE - Perù 9
AE - Emirati Arabi Uniti 7
BE - Belgio 7
CH - Svizzera 7
PY - Paraguay 7
IL - Israele 6
PH - Filippine 6
AZ - Azerbaigian 5
CR - Costa Rica 5
GR - Grecia 5
KZ - Kazakistan 5
TH - Thailandia 5
XK - ???statistics.table.value.countryCode.XK??? 5
DZ - Algeria 4
ET - Etiopia 4
EU - Europa 4
GH - Ghana 4
JM - Giamaica 4
LV - Lettonia 4
NP - Nepal 4
PS - Palestinian Territory 4
RO - Romania 4
TN - Tunisia 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
AL - Albania 3
BW - Botswana 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
HR - Croazia 3
KG - Kirghizistan 3
LB - Libano 3
NI - Nicaragua 3
OM - Oman 3
AO - Angola 2
BO - Bolivia 2
GT - Guatemala 2
LY - Libia 2
MK - Macedonia 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
TJ - Tagikistan 2
UY - Uruguay 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BJ - Benin 1
BN - Brunei Darussalam 1
Totale 9.794
Salva come PNG Salva come JPEG
Città #
Ashburn 614
Singapore 538
Hong Kong 403
Santa Clara 355
San Jose 342
Dallas 246
Chandler 213
Shanghai 212
Fairfield 184
Sofia 123
Florence 116
New York 114
Boardman 111
Beijing 100
Woodbridge 100
Los Angeles 95
London 94
Houston 93
Abidjan 90
Ho Chi Minh City 90
Ann Arbor 86
Tokyo 85
Munich 75
Hanoi 72
Wilmington 72
Princeton 71
Milan 69
Helsinki 65
Lauterbourg 60
Dakar 57
Seattle 57
Istanbul 56
Cambridge 55
Lawrence 53
Pisa 52
Serra 49
Medford 44
Rome 37
Frankfurt am Main 33
Lagos 33
Turku 33
Council Bluffs 32
Mumbai 29
Redwood City 28
Kent 27
Rio de Janeiro 27
Redondo Beach 26
Dong Ket 25
São Paulo 25
Bremen 24
Buffalo 24
Vienna 23
Warsaw 23
Hyderabad 22
Chicago 20
Massa 19
Hefei 18
Jakarta 18
San Francisco 17
Washington 17
Amsterdam 16
Ottawa 16
Tashkent 16
Da Nang 15
San Diego 15
Chennai 14
Denver 14
Fuzhou 14
Santiago 14
Johannesburg 13
Mexico City 13
Ogden 13
Orem 13
Baghdad 12
Nuremberg 12
Brooklyn 11
Düsseldorf 11
Modugno 11
Curitiba 10
Haiphong 10
Manchester 10
Norwalk 10
Paris 10
Atlanta 9
Bengaluru 9
Livorno 9
Melbourne 9
Mountain View 9
Nairobi 9
Phoenix 9
Riyadh 9
Sydney 9
Toronto 9
Amman 8
Belo Horizonte 8
Cairo 8
Cascina 8
Dublin 8
Jeddah 8
Marseille 8
Totale 6.330
Salva come PNG Salva come JPEG
Nome #
The Anti-TNF Drugs and the Risk of Lymphoma, Skin Cancer and Melanoma: A Signal Detection Analysis 203
Expected and actual adverse drug-drug interactions in elderly patients accessing the emergency department: data from the ANCESTRAL-ED study 200
Trajectories of oral budesonide use in Crohn's disease cohort of Tuscan patients (Italy) 195
Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects 193
Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study 177
Longitudinal adherence trajectories to biologic disease modifying anti-rheumatic drugs in Tuscany, Italy 174
Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy 173
Allopurinol adherence among patients with gout: an Italian general practice database study 171
Diabetes drugs and the incidence of solid cancers: a survey of the current evidence 165
Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy) 164
Validation test for algorithms to identify rheumatoid arthritis patients in the Tuscan healthcare administrative databases 158
Antibiotic Drugs and Unresolved Sensory Side Effects: Analysis of Eudravigilance Database of Suspected Adverse Drug Reaction Reports 158
Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons 156
Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis 155
Raynaud’s Phenomenon Associated with Calcitonin Gene-Related Peptide (CGRP) Antagonists: a Disproportionality Analysis on VigiBase 149
Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs 148
The usefulness of listening social media for pharmacovigilance purposes: a systematic review 147
Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database 143
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline 143
Fatal Fat Overload Syndrome Following Intravenous Lipid Emulsion Administration as Antidote in Suspected Anesthetic Intoxication: A Fatal Medication Error. 140
Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy 140
Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study) 140
Time to biologic treatment and to total colectomy associated with diagnostic delay in ulcerative colitis: Analysis of an Italian regional administrative healthcare database 138
Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies 137
QT Interval Prolongation and Hydroxyzine: A Retrospective Cohort Analysis on Hospitalized Elderly Patients 135
Recommendations by the Tuscan Health Authority to Use Infliximab-Biosimilar in the Clinical Practice: Safety Impact 134
Potential and Actual Drug-Drug Interactions in Elderly Patients Admitted to an Emergency Department: Data from the ANCESTRAL-ED Study 133
Anticoagulant Therapy and Risk of Bleeding in Patients with Atrial Fibrillation of Four Italian Regions: The TYRION Study 133
Trajectories of use of biologic disease modifying antirheumatic drugs in rheumatoid arthritis: A cohort study of Tuscan patients, Italy 132
Bleeding Related to Oral Anticoagulant Drugs as Cause of Emergency Department Admission: Analysis of Data from the Tuscan MEREAFaPS Network 132
Listening Social Media for Pharmacovigilance Objectives: Which Usefulness? 132
Utilization patterns and healthcare accesses of JAKi used in rheumatoid arthritis patients in Tuscany: The LEONARDO study 131
Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases 130
Adverse drug reactions in oncoLogy: intEnsive monitoring program on biotechnological anD taRget therapies in Oncologic patientS-ALEXANDROS observational study 128
Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study 128
Disproportionality Analysis of ‘‘Early-Onset’’ Tardive Dyskinesia Stratified by Time to Onset Using FAERS Database. 126
IntenSive Monitoring Program of TeratOgen and Non-Teratogen Risk of Drugs During Pregnancy: the STORK Project 126
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future 126
Unresolved gustatory, olfactory and auditory adverse drug reactions to antibiotic drugs: a survey of spontaneous reporting to Eudravigilance 125
THE ECONOMIC IMPACT OF THE INTRODUCTION OF INFLIXIMAB-BIOSIMILAR: AN EMPIRICAL ANALYSIS USING THE TUSCANY HEALTHCARE ADMINISTRATIVE DATABASES 125
Erratum to: Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System (Drug Safety, (2023), 46, 3, (283-295), 10.1007/s40264-022-01269-x) 123
A clinician network for sharing patients experiences in pharmacovigilance: the PHARMACOWIKILANCE project 120
Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients 119
Estimation of Theoretical Cost Preventability Achievable with an Effective Pharmacovigilance Activity in a Pharmacovigilance Regional Centre in Italy 119
Characterization of the Risk of Bleeding with Novel Oral Anticoagulants and Warfarin: A Pilot Case-Control Study 118
The Economic Impact of the Introduction of Infliximab-Biosimilar: Preliminary Results from a Study on Rheumatologic Patients in Tuscany, Italy 117
Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis 116
Evaluation of drug-utilization and healthcare facilities use in patients with ulcerative colitis and treated with biologic therapy using data of an Italian healthcare administrative database: Results from michelangelo study 114
Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease 113
Anticoagulant Therapy in Patients with Atrial Fibrillation and Risk of Bleeding: Interim Analysis: Tyrion Study 111
Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments 111
Update of Certolizumab Pegol Safety Profile: A Systematic Review and Meta-Analysis 111
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients 110
Discontinuation rate to biologic and targeted synthetic DMARDs in rheumatoid arthritis patients: Systematic review and meta-analysis 109
Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project 109
Analysis of the Drug Related Emergency Department Admissions in Tuscany: The FARO Project 107
The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance 107
A Model-Based Analysis on Direct Costs of Adverse Drug Events and Related Cost-Savings Achievable by their Prevention in Tuscany, Italy 104
Switching from infliximab-originator to infliximab-biosimilar in rheumatologic patients: The clinical impact in Tuscan Region, Italy 100
A regulatory overview of biosimilars across selected countries 99
Italian Emergency Department Visits and Hospitalizations for Outpatients’ Adverse Drug Events: 12-Year Active Pharmacovigilance Surveillance (The MEREAFaPS Study) 99
Challenges of Pharmacovigilance in the Neonate 96
Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis 95
Muscular adverse drug reactions associated with proton pump inhibitors: a disproportionality analysis using the Italian National Network of Pharmacovigilance database 94
Potential missed diagnoses of Crohn's disease in tertiary care: impact on drug utilization and healthcare facilities use 93
Supporting the Spontaneous Reporting by Health Care Professionals of the University Hospital of Pisa, Italy: a Pilot Project from the Unit of Adverse Drug Reactions Monitoring 91
Severe Cardiac Events Following Treatment with Trastuzumab in Women with Breast Cancer: A Meta-Analysis of Clinical Trials and Cohort Studies 91
Oral Presentation: Signal of Hypertension Associated with COVID-19 Vaccination: VigiBase (R) Data and Evidence from Real World 87
Assessment of Healthcare Facilities Associated with JAKi Drugs Used in Rheumatoid Arthritis Patients in Tuscany, Italy: The LEONARDO 85
Fat overload syndrome following intravenous lipid emulsion administration as antidote in suspected anesthetic intoxication: insights from a clinical and forensic case experience 84
Communicating Drug Safety 83
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence 78
Oral Presentation: Accesses to Emergency Department and Hospitalizations in New Users of Biologic Therapies for Ulcerative Colitis in Tuscany: The MICHELANGELO Study 77
Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option 76
Biosimilars approvals by thirteen regulatory authorities: A cross-national comparison 75
COVID-19 Vaccines and Thromboembolic Events with Thrombocytopenia: Data from Italian Pharmacovigilance Public Database 73
Signals of Possibly Persistent Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Disproportionality Analysis Using the EudraVigilance Database 69
Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall 64
A Cross-National Comparison of Biosimilars Pricing in Argentina, Australia, Brazil, and Italy 63
Unresolved Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Signal Detection Analysis on Publicly Accessible Eudravigilance Data 58
Risk of Hospitalization Associated with Cardiovascular Medications in the Elderly Italian Population: A Nationwide Multicenter Study in Emergency Departments 55
Authors’ response: Inhibiting IL-6 in COVID-19: we are not sure that sgp130(fc) can affect only the trans-signaling receptor pathway of IL-6 52
Drug Safety and Relevant Issues in the Real-World 51
Real-world evidence and pharmacovigilance: workshop of the Italian Epidemiological Association and of the Italian Society of Pharmacology 27
Totale 9.996
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.910
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.910
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021179 0 0 0 0 0 0 0 0 0 0 20 159
2021/2022825 12 31 79 89 124 111 34 48 48 22 55 172
2022/20231.112 148 205 78 65 88 98 32 53 230 2 109 4
2023/2024927 34 53 64 32 102 149 100 60 39 46 119 129
2024/20253.046 43 116 114 216 222 380 232 101 306 354 321 641
2025/20263.195 348 243 345 329 396 201 544 146 281 336 26 0
Totale 9.996